Condition: Crohns Disease · Colitis, Ulcerative · Arthritis, Psoriatic · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Children's Center for Digestive Healthcare | Atlanta, Georgia, United States | Recruiting |
| Riley Hospital for Children | Indianapolis, Indiana, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| University of Utah | Salt Lake City, Utah, United States | Recruiting |
| Instituto Caici | Rosario, Argentina | Recruiting |
| The Kids Research Institute Australia on behalf of the Centre for Child Health Research | Nedlands, Australia | Recruiting |
| Mater Hospital Brisbane Inflammatory Bowel Diseases | South Brisbane, Australia | Recruiting |
| The Children's Hospital at Westmead | Westmead, Australia | Recruiting |
| Universidade Federal de Goias - Hospital das Clinicas da UFG | Goiânia, Brazil | Recruiting |
| Capital Center For Children's health Capital Medical University | Beijing, China | Recruiting |
| Changzhou No 2 Peoples Hospital | Changzhou, China | Recruiting |
+ 35 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06663332